Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended Decembe...(anding (000's) - basic and diluted ...)

Date:3/5/2009

anding (000's) - basic and diluted 85,118 85,118 ------------------------------------------------------------------------- ------------------------------------------------------------------------- (in thousands of U.S.$, except Year ended share and per share data) December 31, 2007 ------------------------------------------------------------------------- Reported Adjustments Adjusted REVENUE Royalty revenue $ 116,659 $ - $ 116,659 Product sales, net 170,193 2,579 a 172,772 License fees 842 (842) b - ------------------------------------------------------------------------- 287,694 1,737 289,431 ------------------------------------------------------------------------- EXPENSES License and royalty fees 18,652 - 18,652 Cost of products sold 94,949 (2,065) c 92,884 Research and development 53,963 (4,582) d 49,381 Selling, general and administrative 99,315 (16,470) e 82,845 Depreciation and amortization 33,429 (29,971) f 3,458 In-process research and development 8,125 (8,125) g - ------------------------------------------------------------------------- 308,433 (61,213) 247,220 ------------------------------------------------------------------------- Operating (loss) income (20,739) 62,950 42,211 ------------------------------------------------------------------------- Other income (expenses): Foreign exchange gain (loss) (
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study